indazoles has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (38.89) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Beal, MF; Browne, SE; Matthews, RT; Muqit, MM; Schulz, JB | 1 |
| Snyder, SH | 1 |
| Beal, MF; Brouillet, E; Dolan, R; Ferrante, R; Hantraye, P; Matthews, RT; Palfi, S | 1 |
| Anderson, A; Castagnoli, K; Castagnoli, N; Di Monte, DA; Langston, JW; Royland, JE | 1 |
| Beal, MF; Brouillet, E; Ferrante, RJ; Hantraye, P | 1 |
| Delfani, K; Di Monte, DA; Janson, AM; Langston, JW; Royland, JE | 1 |
| Castagnoli, K; Castagnoli, N; Palmer, S | 1 |
| Boireau, A; Bordier, F; Dubedat, P; Imperato, A; Moussaoui, S | 1 |
| Araki, T; Imai, Y; Itoyama, Y; Kato, H; Kurosaki, R; Matsubara, M; Michimata, M; Mikami, T; Muramatsu, Y | 1 |
| Chalimoniuk, M; Langfort, J; Lukacova, N; Marsala, J | 1 |
| Araki, T; Kato, H; Takagi, S; Watanabe, Y; Yokoyama, H | 1 |
| Arán, VJ; Guillén, H; Herraiz, T | 1 |
| Guillén, H; Herraiz, T | 1 |
| Alcantara, SL; Brzozowski, MJ; Iravani, MM; Jenner, P; Rose, S | 1 |
| Herraiz, T | 1 |
| Choi, CL; Cui, W; Han, YF; Hu, SQ; Lee, MY; Mak, SH; Rong, JH; Tsim, WK; Wang, YQ; Xu, DP; Zhang, ZJ | 1 |
| Chong-Fa, L; Jin-Jun, R; Lu, Z; Wen-Ting, Z; Wen-Ya, W; Xiao-Feng, L; Yuan-Yuan, X | 1 |
| Chen, Y; Deng, J; Gao, C; Huo, C; Li, G; Li, GB; Li, YZ; Luo, ZY; Ning, XL; Peng, C; Qian, S; Ren, YL; Wang, M; Wang, SY; Wang, ZY; Wu, Y; Wu, YX; Yang, LL; Yu, JL; Zhu, KR | 1 |
18 other study(ies) available for indazoles and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Oxidoreductases; Animals; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Enzyme Inhibitors; Indazoles; Male; Mice; Mice, Inbred Strains; Neurons; Neuroprotective Agents; Neurotoxins; Nitric Oxide Synthase; Tyrosine | 1995 |
No NO prevents parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Enzyme Inhibitors; Humans; Indazoles; Neurons; Nitric Oxide; Nitric Oxide Synthase; Papio; Parkinson Disease | 1996 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Enzyme Inhibitors; Homovanillic Acid; Hypokinesia; Indazoles; Male; Motor Activity; Neurologic Examination; Neurons; Nitric Oxide Synthase; Papio; Parkinson Disease, Secondary; Substantia Nigra; Videotape Recording | 1996 |
Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Enzyme Inhibitors; Indazoles; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Neurotoxins; Nitric Oxide Synthase | 1997 |
Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Dopamine Agents; Enzyme Inhibitors; Immunohistochemistry; Indazoles; Male; Neurons; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Papio; Substantia Nigra; Tyrosine | 1999 |
7-Nitroindazole prevents 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced ATP loss in the mouse striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Corpus Striatum; Energy Metabolism; Enzyme Inhibitors; Indazoles; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitroarginine | 1999 |
Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Cattle; Corpus Striatum; Dopamine; Indazoles; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Neuroprotective Agents; Neurotoxins; Selegiline | 1999 |
The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Indazoles; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease, Secondary; Riluzole | 2000 |
Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Arginine; Brain Chemistry; Dopamine; Dopamine Agents; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Immunohistochemistry; Indazoles; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Neostriatum; Neurotoxicity Syndromes; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Pargyline; Tyrosine 3-Monooxygenase | 2002 |
Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Count; Cyclic GMP; Disease Models, Animal; Drug Administration Schedule; Gene Expression Regulation; Guanylate Cyclase; Immunohistochemistry; Indazoles; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Parkinsonian Disorders; Time Factors; Tyrosine 3-Monooxygenase | 2006 |
Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Cytoprotection; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activators; Enzyme Inhibitors; Free Radical Scavengers; Glial Fibrillary Acidic Protein; Gliosis; Homovanillic Acid; Indazoles; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Parkinsonian Disorders; Reactive Nitrogen Species; Reactive Oxygen Species; Tyrosine 3-Monooxygenase | 2008 |
Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Free Radical Scavengers; Humans; Indazoles; Mitochondria, Liver; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidation-Reduction; Pyridinium Compounds | 2009 |
Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antioxidants; Carbolines; Chromatography, High Pressure Liquid; Harmine; Humans; Indazoles; Mass Spectrometry; Methylene Blue; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Neurotoxins; Oxidation-Reduction; Selegiline | 2011 |
The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amidines; Animals; Asparagine; Caspase 3; Cell Death; Cell Line, Tumor; Citrulline; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Indazoles; L-Lactate Dehydrogenase; Leupeptins; Mice; Neuroblastoma; Neurotoxins; Nitric Oxide Synthase Type I; Thiophenes; Transfection; Tritium; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2011 |
Evaluation of the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to toxic pyridinium cations by monoamine oxidase (MAO) enzymes and its use to search for new MAO inhibitors and protective agents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Carbolines; Chromatography, High Pressure Liquid; Clorgyline; Enzyme Assays; Harmine; Humans; Indazoles; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Nicotiana; Oxidation-Reduction; Pyridinium Compounds; Recombinant Proteins; Selegiline; Smoke; Vitamin K 3 | 2012 |
Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Apoptosis; Cells, Cultured; Cerebellum; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation; Humans; Indazoles; Indoles; Neurons; Neuroprotective Agents; Neurotoxins; Nitric Oxide; omega-N-Methylarginine; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib | 2014 |
Protective role of 6-Hydroxy-1-H-Indazole in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Indazoles; Male; Mesencephalon; Mice; Neostriatum; Parkinson Disease; Phosphorylation; Substantia Nigra; tau Proteins; Tyrosine 3-Monooxygenase | 2016 |
X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Line, Tumor; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Indazoles; Indoleamine-Pyrrole 2,3,-Dioxygenase; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; Parkinson Disease, Secondary; Protein Binding; Structure-Activity Relationship; Tryptophan Oxygenase | 2021 |